EXPERIMENTAL ACUTE ANTERIOR UVEITIS
实验性急性前葡萄膜炎
基本信息
- 批准号:2164473
- 负责人:
- 金额:$ 20.1万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1994
- 资助国家:美国
- 起止时间:1994-04-01 至 1999-03-31
- 项目状态:已结题
- 来源:
- 关键词:MHC class II antigen T cell receptor acute disease /disorder anergy antigens autoimmune disorder cell adhesion molecules cell population study disease /disorder model hybridomas immunopathology immunotherapy inflammation iridocyclitis laboratory mouse laboratory rabbit laboratory rat major histocompatibility complex melanins model design /development molecular cloning monoclonal antibody oxidoreductase inhibitor passive immunization
项目摘要
The most frequent form of human intraocular inflammation is acute
anterior uveitis (AAU) of unknown etiology. The recurrent nature of
the disease can lead to permanent visual loss from the secondary
complications of cystoid macular edema, posterior subcapsular
cataract or glaucoma. Consequently, it is a major cause of visual
disability in our society.
Until recently, no experimental animal model of AAU existed. In the
most widely studied model of autoimmune intraocular inflammation,
experimental autoimmune uveitis (EAU) to various soluble retinal
proteins, the retina and choroid are the foci of inflammation not
the iris/ciliary body (CB) as in human AAU. We, as well as
Brockhuyse and colleagues, have described a new experimental model
in the Lewis rat which is induced by immunization with a bovine
melanin associated protein derived from the iris/CB and which
mimics human AAU. We refer to it as experimental acute anterior
uveitis (BAAU).
The studies in this proposal are designed to complete the
immunologic characterization of the autoimmune model, to identify
the pathogenic protein and its immunodominant epitopes, to explore
the immunopathogenesis of the disease and to study the efficacy of
various treatment approaches. The opportunity to directly study a
clinically relevant model of intraocular inflammation is exciting
and provides unique possibilities to understand and prevent a
disease which is associated with significant morbidity and which
can only be treated symptomatically, but not cured.
人类眼内炎症最常见的形式是急性的
病因不明的前葡萄膜炎(AAU)。的经常性质
这种疾病可以导致永久性的视力丧失,
黄斑囊样水肿并发症,后囊下
白内障或青光眼。因此,它是视觉的主要原因。
残疾人在我们的社会。
直到最近,还没有AAU的实验动物模型存在。在
最广泛研究的自身免疫性眼内炎症模型,
实验性自身免疫性葡萄膜炎(EAU)对各种可溶性视网膜色素变性的影响
蛋白质,视网膜和脉络膜是炎症的病灶,
虹膜/睫状体(CB),如在人AAU中。我们以及
Brockhuyse和同事描述了一种新的实验模型
在刘易斯大鼠中,其通过用牛免疫诱导
来源于虹膜/CB的黑色素相关蛋白,
模拟人类AAU。我们称之为实验性急性前
葡萄膜炎(BAAU)。
本提案中的研究旨在完成
自身免疫模型的免疫学表征,以鉴定
致病蛋白及其免疫优势表位,探索
疾病的免疫发病机制,并研究
各种治疗方法。直接学习A的机会
眼内炎症的临床相关模型令人兴奋
并提供了独特的可能性,以了解和防止
与显著发病率相关的疾病,
只能治标不治本。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
HENRY Jerrold KAPLAN其他文献
HENRY Jerrold KAPLAN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('HENRY Jerrold KAPLAN', 18)}}的其他基金
Exsomes derived from retinal astrocytes in the regulation of retinal vasculature
视网膜星形胶质细胞衍生的外泌体在视网膜血管系统调节中的作用
- 批准号:
9040963 - 财政年份:2015
- 资助金额:
$ 20.1万 - 项目类别:
P23H Rhodopsin Mutant Swine Model of Reninitis Pigmentosa
P23H视紫红质突变猪色素性肾炎模型
- 批准号:
8047278 - 财政年份:2010
- 资助金额:
$ 20.1万 - 项目类别:
P23H Rhodopsin Mutant Swine Model of Reninitis Pigmentosa
P23H视紫红质突变猪色素性肾炎模型
- 批准号:
8204540 - 财政年份:2010
- 资助金额:
$ 20.1万 - 项目类别:
Targeting drug-delivery nanoparticles to sites of inflammation
将药物输送纳米颗粒靶向炎症部位
- 批准号:
7109581 - 财政年份:2006
- 资助金额:
$ 20.1万 - 项目类别:
Targeting drug delivery nanoparticles to sites of inflammation
将药物输送纳米颗粒靶向炎症部位
- 批准号:
7684130 - 财政年份:2006
- 资助金额:
$ 20.1万 - 项目类别:
Targeting drug delivery nanoparticles to sites of inflammation
将药物输送纳米颗粒靶向炎症部位
- 批准号:
7538931 - 财政年份:2006
- 资助金额:
$ 20.1万 - 项目类别:
相似海外基金
The molecular basis of T cell receptor cross-reactivity between MHC and MR1
MHC 和 MR1 之间 T 细胞受体交叉反应的分子基础
- 批准号:
DP240102905 - 财政年份:2024
- 资助金额:
$ 20.1万 - 项目类别:
Discovery Projects
Machine Learning of Disease Biomarkers from B and T cell Receptor Repertoires
来自 B 和 T 细胞受体库的疾病生物标志物的机器学习
- 批准号:
23K28188 - 财政年份:2024
- 资助金额:
$ 20.1万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
CAREER: Understanding the Impact of Dephosphorylation Kinetics and Adapter Specificity on Synthetic T Cell Receptor Signaling and Function
职业:了解去磷酸化动力学和接头特异性对合成 T 细胞受体信号传导和功能的影响
- 批准号:
2339172 - 财政年份:2024
- 资助金额:
$ 20.1万 - 项目类别:
Continuing Grant
Special Public T Cell Receptor Sequences that Predict Outcomes for Cancer Patients
预测癌症患者预后的特殊公共 T 细胞受体序列
- 批准号:
10577518 - 财政年份:2023
- 资助金额:
$ 20.1万 - 项目类别:
Machine Learning of Disease Biomarkers from B and T cell Receptor Repertoires
来自 B 和 T 细胞受体库的疾病生物标志物的机器学习
- 批准号:
23H03498 - 财政年份:2023
- 资助金额:
$ 20.1万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Impact of T cell receptor signaling on memory CD8+ T cell stemness
T 细胞受体信号传导对记忆 CD8 T 细胞干性的影响
- 批准号:
10676407 - 财政年份:2023
- 资助金额:
$ 20.1万 - 项目类别:
T cell receptor cross-reactivity and structural basis of virus immune escape
T细胞受体交叉反应性和病毒免疫逃逸的结构基础
- 批准号:
22KK0277 - 财政年份:2023
- 资助金额:
$ 20.1万 - 项目类别:
Fund for the Promotion of Joint International Research (Fostering Joint International Research (A))
T-cell receptor mimic affinity reagent generation using an in vivo novel immunogen strategy
使用体内新型免疫原策略生成 T 细胞受体模拟亲和试剂
- 批准号:
10599584 - 财政年份:2023
- 资助金额:
$ 20.1万 - 项目类别:
Mechanical regulation of T cell receptor and co-receptor responses in cancer immunotherapy
癌症免疫治疗中 T 细胞受体和辅助受体反应的机械调节
- 批准号:
10530023 - 财政年份:2022
- 资助金额:
$ 20.1万 - 项目类别:
Inhibition of T-cell Receptor Signaling for Treatment of Adult T-cell Leukemia Lymphoma
抑制 T 细胞受体信号转导治疗成人 T 细胞白血病淋巴瘤
- 批准号:
10684172 - 财政年份:2022
- 资助金额:
$ 20.1万 - 项目类别: